Published in Cancer Weekly, August 30th, 1999
The focus of the agreements is research in the field of cell-based diagnostics for cancer detection, monitoring, and staging. The principal investigator is Jonathan W. Uhr, MD, professor of Microbiology and Internal Medicine.
The SRA is for a period of three years and provides monetary support and other consideration for research into applications and further development of Immunicon's rare-cell detection and analysis platform...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.